MNG40
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.400
- CHOLESTEROL_HOMEOSTASIS+0.295
- HEDGEHOG_SIGNALING+0.241
- KRAS_SIGNALING_DN+0.225
- MYOGENESIS+0.213
- WNT_BETA_CATENIN_SIGNALING+0.163
- INTERFERON_GAMMA_RESPONSE+0.158
- SPERMATOGENESIS+0.148
- ESTROGEN_RESPONSE_LATE+0.117
- E2F_TARGETS+0.113
Top 10 suppressed
- PROTEIN_SECRETION-0.465
- TGF_BETA_SIGNALING-0.351
- KRAS_SIGNALING_UP-0.303
- UNFOLDED_PROTEIN_RESPONSE-0.300
- UV_RESPONSE_DN-0.279
- ANGIOGENESIS-0.272
- OXIDATIVE_PHOSPHORYLATION-0.272
- MTORC1_SIGNALING-0.251
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.234
- MITOTIC_SPINDLE-0.211
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1086 | — | — | 0.740 |
| 2 | TCGA-94-7033-01A-11R-1949-07 | — | cohortSQ1 | 0.735 |
| 3 | MBCProject_4423_T1_RNA | — | B | 0.733 |
| 4 | R30 | — | — | 0.720 |
| 5 | SRR12202495 | — | — | 0.714 |
| 6 | R94 | — | — | 0.702 |
| 7 | TCGA-33-AASL-01A-11R-A405-07 | — | cohortSQ2 | 0.698 |
| 8 | SRR2932834 | — | — | 0.674 |
| 9 | C3N-02252 | — | cohortSQ2 | 0.674 |
| 10 | MDT-AP-0398 | Med | Medulloblastoma | 0.671 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.295 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.241 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.225 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.213 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.163 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.158 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.148 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.117 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.113 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.109 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.091 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.087 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.079 | Idelalisib | — uncovered |
| COAGULATION | 0.061 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.054 | Inavolisib | — uncovered |
| HYPOXIA | 0.044 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.033 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.029 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.025 | Inavolisib | — uncovered |